Publications by authors named "N El Helali"

High-dose levofloxacin was explored in a clinical trial against multidrug-resistant tuberculosis and failed to show increased efficacy. In this study, we used a murine model to explore the efficacy of a dose increase in levofloxacin monotherapy beyond the maximum dose evaluated in humans. A total of 120 4-week-old female BALB/c mice were intravenously infected with 10 CFU of H37Rv wild-type (WT) or isogenic H37Rv mutants harboring GyrA A90V or D94G substitutions; the MICs were 0.

View Article and Find Full Text PDF

Cloxacillin and oxacillin are group M penicillins. The therapeutic monitoring of plasma concentrations of these antibiotics and those of their hydroxymethylated metabolites is of great clinical interest, especially in the choice of an adequate dosage allowing an effective treatment while limiting the occurrence of undesirable effects and the development of bacterial resistance. In this context, we conducted this work aiming at developing and validating a method allowing the determination of cloxacillin and oxacillin as well as the identification of their active metabolites in different biological matrices (CSF and plasma) using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry.

View Article and Find Full Text PDF
Article Synopsis
  • Multidrug-resistant Gram-negative bacteria are a growing public health concern, leading to challenges in treating infections effectively.
  • New antibiotics have been developed to combat these infections, including combinations specifically targeting resistant strains (e.g., ceftolozane/tazobactam, imipenem/relebactam).
  • International guidelines recommend these antibiotics for documented infections, but understanding risk factors like local ecology and prior antibiotic use is crucial for optimizing treatment strategies.
View Article and Find Full Text PDF

Treatment of infective endocarditis (IE) is based on high doses of antibiotics with a prolonged duration. Therapeutic drug monitoring (TDM) allows antibiotic prescription optimization and leads to a personalized medicine, but no study evaluates its interest in the management of IE. We conducted a retrospective, bicentric, descriptive study, from January 2007 to December 2019.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the correlation between linezolid drug levels and the occurrence of severe toxicity in patients being treated for multidrug-resistant tuberculosis (MDR TB) from 2011 to 2017.
  • Severe mitochondrial toxicity was found in 39% of the 146 patients, with higher drug concentrations linked to increased risk of neurotoxicity or myelotoxicity.
  • The results suggest that patients with linezolid trough concentrations above 2 mg/L have a significantly higher chance of developing severe side effects, highlighting the need for careful monitoring and risk evaluation in treatment decisions.
View Article and Find Full Text PDF